The global Minimal Residual Disease Mrd Testing market is expanding as pharmaceutical companies, research institutions, and clinical laboratories invest in advanced molecular diagnostics to support cancer monitoring, treatment response assessment, and early relapse detection. The market was valued at USD 2.9 billion in 2023 and is projected to reach USD 8.42 billion by 2032, growing at a CAGR...
English
Arabic
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek